## **Resource Summary Report**

Generated by FDI Lab - SciCrunch.org on Apr 30, 2024

# Anti-Mouse CD366/TIM-3 (RMT3-23)-162Dy Antibody

RRID:AB\_2687841 Type: Antibody

#### **Proper Citation**

(Standard BioTools Cat# 3162029 (also 3162029B), RRID:AB\_2687841)

#### **Antibody Information**

URL: http://antibodyregistry.org/AB\_2687841

Proper Citation: (Standard BioTools Cat# 3162029 (also 3162029B), RRID:AB\_2687841)

Target Antigen: CD366/Tim-3

**Clonality:** monoclonal

Antibody Name: Anti-Mouse CD366/TIM-3 (RMT3-23)-162Dy Antibody

**Description:** This monoclonal targets CD366/Tim-3

Target Organism: mouse

Clone ID: RMT3-23

Antibody ID: AB\_2687841

Vendor: Standard BioTools

**Catalog Number:** 3162029 (also 3162029B)

**Alternative Catalog Numbers: 3162029B** 

#### **Ratings and Alerts**

No rating or validation information has been found for Anti-Mouse CD366/TIM-3 (RMT3-23)-162Dy Antibody.

No alerts have been found for Anti-Mouse CD366/TIM-3 (RMT3-23)-162Dy Antibody.

#### **Data and Source Information**

Source: Antibody Registry

### **Usage and Citation Metrics**

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at FDI Lab - SciCrunch.org.

Okamoto M, et al. (2023) A genetic method specifically delineates Th1-type Treg cells and their roles in tumor immunity. Cell reports, 42(7), 112813.

Li H, et al. (2022) The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer cell, 40(1), 36.

Wang Y, et al. (2021) Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer cell, 39(10), 1375.

Wei SC, et al. (2017) Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 170(6), 1120.